MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg®. Xervyteg® has the potential if approved, to become the first microbiota...
Read the full article below. Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal...
EMIH is pleased to see Dr. Marty Makary, newly appointed FDA Commissioner, highlight the role of the gut microbiome in human health during his recent interview. His emphasis on the microbiome’s influence aligns strongly with EMIH’s mission to accelerate the...
We caught up with Hervé Affagard, CEO of MaaT Pharma and President of EMIH for an exclusive interview to discuss the far reaching impact of the ARES Phase 3 unprecedented results Read the full interview below. Hervé Affagard talks Phase 3 results, the regulatory...
